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medium risk (OS mean time = 11.6 months, 61%) and other of low risk were obtained 
(OS mean time = 31.7 months, 38%). For NSCLC patients with immunotherapy a 
population of medium risk (OS mean time = 11.2 months, 55%); a population of 
low risk (OS mean time = 23.8 months, 33%); and another of very low risk or long-
term survival were obtained (OS mean time = 55.5 months, 12%). ConClusions: 
Our analyses support the existence of several populations regarding OS among 
advanced stage lung cancer.
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objeCtives: Many company submissions received by Health Technology 
Assessment (HTA) Agencies evaluate the cost effectiveness of interventions which 
impact on survival. An accurate estimate of the survival benefit is required to cal-
culate a reliable estimate of cost effectiveness. Generally the relevant trial data 
is immature and must be extrapolated. Many extrapolation models are available. 
Model choice is critical; different models can lead to different cost effectiveness 
results. The objectives were to review the methods/justification of the survival anal-
ysis used in company submissions to the National Centre for Pharmacoeconomics 
(NCPE). A further aim was to develop NCPE Guidance for the future handling of 
survival analysis. Methods: Relevant submissions to the NCPE (economic evalu-
ations which had dealt with advanced and/or metastatic cancer) were reviewed 
to determine the methods/justification of the survival analysis used. Results: 
Twelve submissions were evaluated. Appropriately, the mean overall survival (OS) 
had been estimated and used in eight cases (67%). Median OS estimates had been 
estimated/used in three (25%). It was unclear which measure had been used in the 
remaining submission. The submissions which had used mean OS estimates were 
further investigated. Parametric model-based extrapolation techniques had been 
used to calculate the mean estimates in all eight. The most popular parametric 
models were the Weibull (n= 3) and the loglogistic (n= 3). The methods used to fit the 
parametric models varied. Most commonly the model was fitted using individual 
patient-level data. Some justification for the choice of extrapolation technique was 
offered in five submissions; AIC +/or BIC were estimated in three and visual inspec-
tion was reported in two. ConClusions: Survival analysis has not been conducted 
appropriately in all HTAs. Justification of the choice of model is not always offered. 
Moving forward, NCPE Guidance is required to ensure that survival analysis using 
patient-level data is conducted appropriately. These will be presented.
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objeCtives: The 2010 Urological Association Guidelines for Management of 
Castrate-Resistant Prostate Cancer (CRPC) recommend docetaxel plus prednisone 
for first-line chemotherapy for symptomatic metastatic CRPC patients who have 
progressed from hormone therapy. Since 2010, several CRPC agents with better toler-
ability and longer survival have launched. These improved therapies are causing a 
shift in practice. The aim of our analysis was to 1) quantify the 3-year mCRPC budget 
impact for the German health system based on the practice shift, and 2) estimate 
the cost per additional month of progression-free survival (PFS). Methods: A con-
ceptual decision analytic model was developed for the German health system to 
estimate the impact on direct medical costs of a therapy shift in CRPC over three 
years. Guideline recommended regimens were represented in model with three 
lines of therapies: palliative, abiraterone, enzalutamide, docetaxel and cabazitaxel. 
Progression in therapy was measured as the duration of PFS. A targeted literature 
search identified US per-patient-per-month costs of docetaxel treated patients (hos-
pitalization= € 954, ambulatory= € 765, ER= € 32, MD= € 318) and were adapted to the 
German health system by applying a published purchase price parity factor. Drug 
costs were based on Ex-factory pricing. Adverse event rates were used as a proxy 
to derive relative resource utilization of other treatments. Utilization of CRPC regi-
mens was informed by interviews with EU opinion leaders. Results: The shift in 
practice pattern is expected to increase the German health system’s 3-year budget 
by € 23 million. The additional cost/month of PFS is estimated to decrease by € 99/
month from € 4,659 for current treatment mix to € 4,560 for future treatment mix 
by year 3. ConClusions: From the German health system’s perspective, a change 
in practice pattern will result in an increase in total budget of € 23 million. The 
reduction in cost/month of PFS of € 99/month indicates the shift in practice will 
use more efficient therapies.
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objeCtives: To evaluate clinical and economic impact of increasing deno-
sumab use compared to zoledronic acid (ZA) in PrCa patients with BM to a 
MCO. Methods: An economic model was developed to estimate clinical and eco-
nomic impact to a 1-million-member US MCO of introducing denosumab as bone 
targeting agent (BTA) for prevention of SREs in PrCa patients with BM. Total number 
of patients receiving BTA was estimated based on disease prevalence and treat-
ment eligibility in this population. The real-world SRE rates in ZA-treated patients 
were derived from a large commercial database and used together with the trial-
(66.0%) AF patients and 406 (66.1%) PF patients were classified in “better responders” 
subgroup. Lognormal and loglogistic distributions were the 2 distributions provid-
ing the best fit to the observed OS data, with very similar and good fit. Mean OS 
over 15-years using loglogistic distribution was 24.8 vs. 18.6 months for AF and PF, 
respectively. ConClusions: Post-hoc analysis suggested that the “better respond-
ers” subgroup of patients within VELOUR derived enhanced survival benefit with 
the AF combination. The results highlight the therapeutic benefit of AF in clinically 
relevant patient subpopulations.
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objeCtives: As cancer control strategies have become more successful, issues 
around survivorship have become increasingly important to researchers and policy 
makers. The aim of this study was to examine the role of a range of clinical and 
socio-demographic variables in explaining variations in survival after prostate 
cancer diagnosis, paying particular attention to the role of health care provider(s) 
(i.e. private vs. public) and socio-economic status. Methods: Data were extracted 
from the National Cancer Registry Ireland, for patients diagnosed with prostate 
cancer from 1998-2009 (N= 26,183). A series of multivariate Cox and logistic regres-
sion models were used to examine the role of health care provider and socio-
economic status (area-based deprivation) on survival, controlling for age, stage, 
Gleason grade, marital status and region. Survival was based on all-cause mortal-
ity. Results: Individuals who were treated in a private care setting were more 
likely to have survived than those who had not, when other factors were controlled 
for. A socio-economic gradient was evident with respect to marital status, region 
of residence, clinical stage and Gleason grade. The effect of socio-economic status 
was modified by health care provider, such that risk of death was higher in those 
of lower socio-economic status for men treated by public, but not private, provid-
ers. ConClusions: The role of health care provider (a proxy for voluntary private 
insurance) and socio-economic status in survival of men with prostate cancer may 
give rise to equity concerns regarding the operation of the Irish health care system 
and warrants further investigation.
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objeCtives: There are few treatments available for advanced melanoma and sur-
vival rates are low. While the incidence of the disease continues to rise, only two 
new treatments have come to the market recently: ipilimumab and vemurafenib. 
Ipilimumab is indicated in Europe for the treatment of advanced melanoma in 
adults who have received prior therapy. Ipilimumab has demonstrated a statistically 
significant improvement in overall survival in 2 Phase III RCTs. Prolonged survival 
(> 2 years in some patients) has been shown (MDX020 & 024). Methods: Data from 
the MDX010-20 trial, which was conducted in previously treated patients with a 
maximum follow up duration of 55 months, was used to develop an economic model 
for health technology assessment in England & Wales. This model has been used 
to predict the conditional survival (CS) of patients treated with ipilimumab (based 
on both ipilimumab containing arms) compared to gp100 – the active control. The 
model used patient level Kaplan–Meier data for the first 18 months, parametric 
curves fitted to the patient level data from 18 months to 5 years, and published AJCC 
registry data beyond 5 years. Results: The curves were a good fit to the MDX010-20 
trial data (MAE 0.003) and consistent with published Phase II data (which provides 
a longer time horizon). Given an ipilimumab patient has survived 2 years, the mod-
elled probability of being alive at 5 years is 67% (49%,79%) (gp100: 15% [9%,21%]) and 
at 10 years is 54% (39%, 63%) (gp100: 2% [1%,3%]). ConClusions: The model shows 
that a substantial proportion of patients treated with ipilimumab surviving to 2 
years are likely to have sustained survival benefits: more than 50% of ipilimumab 
patients surviving to 2 years are alive at 10 years, with 29% remaining alive at 20 
years. This level of sustained survival is not shown by gp100 patients.
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objeCtives: To ascertain the existence of several populations regarding overall sur-
vival (OS) in patients with advanced non-small-cell lung cancer (NSCLC). Methods: 
Data of OS from the Cuban National Cancer Registry (CNCR) and from Cuban mul-
ticentre trials of immunotherapy were analysed with a lognormal mixed model 
assuming 1 to 6 underlying populations. The Bayesian Information Criterion (BIC) 
was used to select the best model fitted to the data in all cases. Results: The CNCR 
provided data for 31133 patients diagnosed with lung cancer since January 1998 
until December 2008. Of those, 7286 patients presented stages IIIb-IV of NSCLC at 
diagnosis and were selected for analysis. The immunotherapy Cuban trials provided 
data for more than 750 patients enrolled in 8 trials conducted since 1997 until 2010. 
The mixed model applied to CNCR data separated 4 populations: very high risk (OS 
mean time = 0.62 months, 23% of the sample); high risk (OS mean time = 3.1 months, 
34%); medium risk (OS mean time = 9.2 months, 35%); and low risk (OS mean time 
= 29.1 months, 8%). Results for clinical trials separated 2 populations for controls 
and 3 populations for the immunotherapy groups. For controls a population of 
